Working… Menu

Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00277576
Recruitment Status : Completed
First Posted : January 16, 2006
Last Update Posted : November 21, 2008
Information provided by:

Brief Summary:
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to reduce hepatitis B disease.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis B Biological: ppdpSC18 administered by PMED Phase 1

Detailed Description:
Hepatitis B virus (HBV) is responsible for the most common form of parenterally transmitted viral hepatitis. It is estimated that approximately 350 million people worldwide are persistent carriers of the virus and it is a major cause of acute and chronic infections of the liver, with significant associated morbidity and mortality. Chronic infection occurs in 98% of new-born children infected by vertical transmission from the mother and in 5% of individuals infected after 2 years of age. About 25% of these subjects will progress to cirrhosis and 20% of this subgroup will develop hepatocellular carcinoma - one of the most common cancers world wide. HBV is a non-cytopathic virus and liver injury is mainly mediated by the host immune response against virus-infected liver cells and by the production of inflammatory cytokines. A vigorous, polyclonal and multispecific cytotoxic and helper T cell response to HBV is readily detectable in the peripheral blood of subjects with acute self-limited hepatitis B, but is weak, antigenically restricted (mono- or oligospecific) or undetectable in subjects with chronic infection. A vigorous T cell response is thus believed to be responsible for the elimination of the hepatitis B virus. The aim of a therapeutic vaccine would be to enhance natural responses by boosting the appropriate cellular immune response to HBV. The purpose of this study is to evaluate the safety and tolerability profile of the pPDPSC18 DNA vaccine as administered by Particle Mediated Epidermal Delivery (PMED )

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Phase I, Multi-Centre, Randomised, Placebo-Controlled, Dose Escalation Study to Assess Local & Systemic Tolerability of Therapeutic DNA Plasmid pdpSC18 Vaccine Administered by Particle Mediated Epidermal Delivery Using PowderJect ND10 Delivery System in Subjects With Chronic Hepatitis B Infection
Study Start Date : January 2006
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Adverse Events at all visits, vaccine site evaluations, laboratory parameters pre and post vaccination

Secondary Outcome Measures :
  1. The secondary endpoints will assess the effect of the Investigational Product on:
  2. immunological response to vaccine at each visit
  3. clinical response to vaccine at each visit

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Otherwise healthy, treatment naïve subjects with chronic well compensated, eAg positive HBV infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00277576

Layout table for location information
Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
19/F Prince of Wales Hospital
Shatin, Hong Kong
Alice Ho Miu Ling Nethersole Hospital
Tai Po, N. T., Hong Kong
National University Hospital
Singapore, Singapore, 119074
Singapore General Hospital
Singapore, Singapore, 169608
Cathay General Hospital
Taipei, Taiwan, 106
Chang Gung Memorial Hospital - Linko
Taoyan, Taiwan, 33
Siriraj Hospital
Bangkok, Thailand
Maharaj Nakorn Chiangmai Hospital
Chiang Mai, Thailand
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Henry LY Chan Prince of Wales Hospital
Principal Investigator: Nancy Leung Alice Ho Miu Ling Nethersole Hospital
Principal Investigator: Seng Gee Lim National University Hospital, Singapore
Principal Investigator: Wan Cheng Chow Singapore General Hospital
Principal Investigator: Sien-Sing Yang Cathay General Hospital
Principal Investigator: I Shyan-Sheen Chang Gung Memorial Hospital - Linko
Principal Investigator: Satawat Thongsawat Maharaj Nakorn Chiang Mai Hospital
Principal Investigator: Tawesak Tandwandee Siriraj Hospital
Principal Investigator: Man Fung Yuen Queen Mary Hospital, Hong Kong

Layout table for additonal information Identifier: NCT00277576     History of Changes
Other Study ID Numbers: PM HBV-001
First Posted: January 16, 2006    Key Record Dates
Last Update Posted: November 21, 2008
Last Verified: November 2008
Keywords provided by PowderMed:
DNA vaccine
Hepatitis B Virus
Particle Mediated Epidermal Delivery
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Immunologic Factors
Physiological Effects of Drugs